BiotechTube

busulfan + PEG-ADA ERT

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

ADA-SCID

Conditions

ADA-SCID

Trial Timeline

Aug 2, 2013 → Aug 27, 2018

NCT ID
NCT01852071

About busulfan + PEG-ADA ERT

busulfan + PEG-ADA ERT is a phase 1/2 stage product being developed by Allergy Therapeutics for ADA-SCID. The current trial status is completed. This product is registered under clinical trial identifier NCT01852071. Target conditions include ADA-SCID.

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT01852071Phase 1/2Completed

Other Products from Allergy Therapeutics

Atripla (r) + Efavirenz + Truvada + Rifampin/isoniazid/pyrazinamide/ethambutol FDC + Rifampin/isoniazid FDC + IsoniazidApproved
80
Doravirine 100 Mg + Integrase strand transfer inhibitors + Tenofovir alafenamide/emtricitabine + tenofovir disproxil fumarate/emtricitabineApproved
80
Sofosbuvir/Velpatasvir (SOF/VEL)Approved
80
Transdermal estradiol gel + Micronized Progesterone + Placebo for estradiol gel + Placebo for micronized progesteroneApproved
80
Efavirenz + Emtricitabine/Tenofovir disoproxil fumarateApproved
80